依达拉奉治疗急性脑梗死的临床观察及其对IL-13的影响  

The Effects of Edaravone on Treatment of Acute Cerebral Infarction and the Changes of Interleukin-13 in Patients'Plasma

作　　者：郜旭[1] 吴秀萍[1] 田旻[1] 

机构地区：[1]哈尔滨医科大学第一临床医学院干部二病房,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2007年第10期1543-1545,共3页Progress in Modern Biomedicine

摘　　要：目的:观察依达拉奉对急性脑梗死的临床疗效及其对血浆白细胞介素13水平的影响。方法:60例脑梗死病例随机分为依达拉奉组及对照组,两组均采用血栓通注射剂作为基础治疗,前者加用依达拉奉静脉滴注、1日2次、共2周。用欧洲卒中评分评价临床神经功能情况,用ELISA法对血浆白细胞介素13水平进行检测。结果:依达拉奉组临床疗效明显优于对照组,治疗后与对照组相比白细胞介素13水平下降较快。结论:依达拉奉治疗急性脑梗死有效,而且安全。Objective： To observe the efficacy of Edaravone in treatment of acute cerebral infarction and its influence on the level of Interleukin-13 in patients＇ plasma. Methods： The sixty cases with acute cerebral infarction were divided into two groups randomly, both of which were treated with Xueshuantong injection as a basic treatment. Edaravone injection was added to the test group by intra- venous drip two times every day for two weeks. The neurological ftmction was evaluated with ESS, and the level of Interleukin-13 in plasma was detected with ELISA Method. Results： The clinical effect in the test groups was observed significantly better than the control group, the level of Interleukin-13 in plasma in the test group decreased more rapidly than that of control group after treatment. Conclusion： Edaravone injection was effective and safe in treatment of acute cerebral infarction.

关 键 词：依达拉奉 急性脑梗死 白细胞介素13 临床研究 

分 类 号：R743.3[医药卫生—神经病学与精神病学]